The firms will jointly invest in establishing a joint venture company in China, and Autobio has also invested €10 million in Mobidiag.
Agena has an ongoing partnership with Guangzhou-based DaRui to develop MassArray-based diagnostics for cancer and inherited diseases for the Chinese market.
The firm's next-generation sequencing diagnostic test analyzes tumor samples from multiple genomic mutations that are targeted by therapies for non-small cell lung cancer.
MGI received medical device certification clearance for its MGISEQ-200 and MGISEQ-2000 instruments.
The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.
The kits cover the primary genetic targets currently used for assessing the compatibility of hematopoietic cell donors with recipients.
Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round.
Through the deal, the companies aim to bring new next-generation sequencing-based oncology diagnostic kits to the Chinese market.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.